Vulnerable Plaque Natural History Key To Device Trial, Swift Approvals
This article was originally published in The Gray Sheet
Executive Summary
Clinical trials supporting devices and diagnostics for vulnerable plaques (VP) should include analysis of the natural history of the vascular disease, according to FDA Office of Device Evaluation's Donald Jensen